KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Current Liabilities: 2018-2025

Historic Total Current Liabilities for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $359.0 million.

  • Esperion Therapeutics' Total Current Liabilities rose 116.45% to $359.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $359.0 million, marking a year-over-year increase of 116.45%. This contributed to the annual value of $246.2 million for FY2024, which is 57.62% up from last year.
  • Esperion Therapeutics' Total Current Liabilities amounted to $359.0 million in Q3 2025, which was up 20.16% from $298.8 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Total Current Liabilities high stood at $359.0 million for Q3 2025, and its period low was $73.4 million during Q4 2021.
  • Over the past 3 years, Esperion Therapeutics' median Total Current Liabilities value was $165.9 million (recorded in 2024), while the average stood at $197.9 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first declined by 22.02% in 2021, then soared by 116.45% in 2025.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' Total Current Liabilities stood at $73.4 million in 2021, then increased by 25.84% to $92.3 million in 2022, then spiked by 69.24% to $156.2 million in 2023, then spiked by 57.62% to $246.2 million in 2024, then soared by 116.45% to $359.0 million in 2025.
  • Its last three reported values are $359.0 million in Q3 2025, $298.8 million for Q2 2025, and $271.0 million during Q1 2025.